Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    National Security
    Science & Regulatory
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Investor Forum
    BIO Asia-Taiwan

    July 15-19, 2026
    Taipei, Taiwan

    BIO Patient & Health Advocacy Summit
    BIO Patient Advocacy Changemakers Event

    October 22-23, 2026
    Washington, D.C

    BIO Asia-Taiwan
    BIO Europe

    November 9-11, 2026
    Cologne, Germany

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyNational SecurityScience & RegulatoryAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3199 results found
Expand All
Apply All
3199 results found

How states can respond to the coronavirus
Share
Bio.News  •  March 11, 2020
We’re staying on top of all the coronavirus news, including a Texas House of Representatives hearing yesterday, where we testified on government and business preparedness and response. We’re also reading a food innovation thought leader’s new blog on why our brains make certain food choices—and how we can use that knowledge to combat myths about food biotech. Here are around 870 words, or 4 minutes, 20 seconds.
Read More

We launched a Coronavirus Business Resource Center
Share
Bio.News  •  March 10, 2020
We launched a Coronavirus Business Resource Center to help companies navigate the coronavirus—keep reading for details. We also have news on whether or not Congress will self-quarantine, as well as a podcast on sustainable food innovations driven by biotech to help you take your mind off the coronavirus, in 765 words, 3 minutes, 50 seconds.
Read More

The truth about insulin pricing
Share
Bio.News  •  March 9, 2020
It’s Podcast Monday. I AM BIO Episode 4, Trying Our Patients, is now available—and if you care about the impact of drug pricing legislation on new cures, you won’t want to miss it. Don’t forget to rate, review, and subscribe wherever you get your podcasts. (Apple, Spotify, and Google)While the spread of the coronavirus and the administration’s “shift in tone” will dominate the news this week, we also want to take a look at two other important issues for the biotech industry: the truth about insulin pricing, and the White House’s response to a court ruling on biofuels exemptions. Here are just under 1,000 words, about 4 and a half minutes.
Read More

BIO Submits Letter to Office of Management and Budget on Part 340
Share
Agriculture & Environment, Food & Farm Innovation  •  Letters, Testimony & Comments  •  March 6, 2020
Each of the below signatories submitted comments to the United States Department of Agriculture on the June 6, 2019, proposed rule regarding the movement of certain genetically engineered (GE) organisms [Docket No. APHIS-2018-0034] (OMB RIN 0579-AE47). Those comments reflect the priorities and recommendations of our individual organizations as the Agency contemplates its role in the regulation of agricultural biotechnology. While our organizations may not be aligned in all aspects of our comments on the proposed rule, including the ability of developers to self-determine that they meet proposed exemptions, one area in which we do broadly agree relates to the need for pre-market notification from developers to the Agency, which would provide regulatory certainty for developers and additional information to the marketplace and consumers. We believe there is an opportunity for this rule to do more in that regard.
Read More

BIO Statement Urging USDA Adoption of Pre-Market Notification Process within Biotech Reg System
Share
Press Release  •  March 6, 2020
Washington, D.C. (March 6, 2020) – The following statement can be attributed to Dana O’Brien, BIO’s Executive Vice President for Food & Agriculture urging USDA to establish a pre-market notification process within its plant biotechnology regulatory system: “BIO’s members are excited about harnessing the potential of biotechnology to solve big challenges, like mitigating climate change, improving biodiversity, and reducing food waste. We understand that for society to fully realize the benefits of food and farm innovation, science-based policy and public support must co-exist. BIO is committed to building the diverse coalitions needed to foster greater public confidence and bring new agricultural solutions to the market.   “BIO is pleased to join with a diverse group of stakeholders in urging USDA to establish a ‘mandatory notification process’ within the Department’s new plant biotechnology regulatory system. This mandatory process would provide innovators with an opportunity to affirm that a plant meets an exemption while providing additional information to the marketplace and consumers. We hope USDA will support this commonsense policy outcome.”
Read More

Everything you need to know about the coronavirus today
Share
Bio.News  •  March 6, 2020
It was another busy week in the fight to contain the coronavirus—but policymakers and the biopharma industry are coming together to find solutions. Here’s the latest news from Washington and BIO members, in about 700 words, or 3 and a half minutes.
Read More

BIO Testifies on Biobased Products to Address Plastic Waste
Share
Letters, Testimony & Comments  •  March 6, 2020
The Biotechnology Innovation Organization (BIO) is pleased to submit a statement for the record to the United States House of Representatives Committee on Energy and Commerce Subcommittee on Environment and Climate Change hearing entitled, “Reduce, Reuse, Recycle, Reform: Addressing America’s Plastic Waste Crisis.”
Read More

How biotech can lead us to a plastic-free future
Share
Bio.News  •  March 5, 2020
There’s more news today on the coronavirus response, including what to expect from the emergency funding package as well as a new partnership between two BIO members, Vir and Alnylam. Be sure to check back tomorrow for more details. In the meantime, we’ve got a recap of yesterday’s hearing on how to address the plastic waste crisis, as well as more on the CAR T-cell payment problem, in about 800 words, just under 4 minutes.
Read More

The coronavirus is no match for science—but we must finish the job
Share
Bio.News  •  March 4, 2020
We’re halfway through the week. Today, BIO CEO Jim Greenwood published a must-read op-ed in Morning Consult about the industry’s coronavirus response. We’re also looking at why biotech is key to a healthy diet, and the latest coronavirus news from Capitol Hill, in 815 words, or about 4 minutes.
Read More

The coronavirus is no match for science—but we must finish the job
Share
Bio.News  •  March 4, 2020
We’re halfway through the week. Today, BIO CEO Jim Greenwood published a must-read op-ed in Morning Consult about the industry’s coronavirus response. We’re also looking at why biotech is key to a healthy diet, and the latest coronavirus news from Capitol Hill, in 815 words, or about 4 minutes.
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 243
  • 244
  • 245
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO Investment and Growth Summit
BIO Partnering™ for Oncology
BIO International Convention
BIO Partnering™ at JPM Week
BIO Patient Advocacy Changemakers Events
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO